Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2

ConclusionOnce-daily netarsudil/latanoprost FDC produced statistically significant and clinically relevant reductions in mean IOP that were statistically superior to IOP reductions achieved by netarsudil and latanoprost monotherapy. Results of the pooled efficacy and safety analyses were consistent with the individual studies.Trial registrationClinicalTrials.gov identifiers, NCT02558400 and NCT02674854.

http://link.springer.com/10.1007/s12325-020-01277-2

Source: Advances in Therapy - March 11, 2020 Category: Drugs & Pharmacology Source Type: research